title: [Effectiveness of 23-valent penumococcal polysaccharide and split-virus influenza vaccines to prevent respiratory diseases for elderly people].
abstract: OBJECTIVE
  To assess the effectiveness of 23-valent penumococcal polysaccharide vaccine (PenV23) and Split-Virus influenza vaccine (InfV-B) for preventing upper respiratory diseases in the aging population.
  
  
  METHODS
  151 people aged > or =60 years who inoculated the PenV23 and InfV-B vaccines at clinics during 2005 as trial group, and 188 people aged > or =65 years didn't administered as control guoup from some comminity. On base line survey, both guoups were followed up two years after vaccination about incidence, hospitalization rate, treatment and direct medical cost.
  
  
  RESULTS
  The vaccine of PenV23 and InfV-B vaccination in upper respiratory tract infection was 60% [(odds ratio OR) = 0.35, 95% CI (0.153-0.794)] and the difference between the 2 groups was significant (P = 0.009). The people had recevied both vaccines, the mean duration of hospitalization in vaccinated vs unvaccinated control peple was 20.00 days: 24.19 days (t = 5.82, P < 0.001). Benefit-cost ratio was 4.03, and the net benefit was Yen 177994.86.
  
  
  CONCLUSIONS
  Incidence of influenza-like illness for the elderly people in the community decreased by administered PenV23 ahd InfV-B vaccine. This vaccines had high cost-benefits.
authors: Rizhao Municipal Center for Disease Control and Prevention, Rizhao 276826 Shandong, China.
authors: Mao-ci
authors: MC
authors: Wang
authors: Tai-ping
authors: TP
authors: Wang
authors: Shao-ming
authors: SM
authors: Yang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000276:immunology*; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000191:economics / Q000276:immunology*; D007251:Influenza, Human / Q000191:economics / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000191:economics / Q000276:immunology*; D012141:Respiratory Tract Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination / Q000191:economics
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines